Search

Your search keyword '"Carvalho JF"' showing total 446 results
Start Over Author "Carvalho JF"
446 results on '"Carvalho JF"'

1. Monitoring the Efficacy of Chloroquine-Primaquine Therapy for Uncomplicated Plasmodium vivax Malaria in the Main Transmission Hot Spot of Brazil

Author

Rodrigo M. Corder, de Melo Gnp, de Sousa Tn, de Carvalho Jf, Lais Camoese Salla, Priscila T. Rodrigues, Simone Ladeia-Andrade, Marcelo U. Ferreira, Maria J. Menezes, Silvino Acr, and Odailton Amaral Nery

Subjects
Adult, Male, medicine.medical_specialty, Primaquine, Adolescent, Sulfadoxine, medicine.medical_treatment, 030231 tropical medicine, Plasmodium vivax, Drug resistance, Epidemiology and Surveillance, Antimalarials, Young Adult, 03 medical and health sciences, 0302 clinical medicine, Pharmacotherapy, Chloroquine, Internal medicine, parasitic diseases, Malaria, Vivax, medicine, Humans, Pharmacology (medical), Child, Aged, Pharmacology, 0303 health sciences, biology, 030306 microbiology, business.industry, Middle Aged, medicine.disease, biology.organism_classification, Treatment Outcome, Infectious Diseases, Child, Preschool, Concomitant, Drug Therapy, Combination, Female, business, Brazil, Malaria, medicine.drug
Abstract

Emerging Plasmodium vivax resistance to chloroquine (CQ) may undermine malaria elimination efforts in South America. CQ-resistant P. vivax has been found in the major port city of Manaus but not in the main malaria hot spots across the Amazon Basin of Brazil, where CQ is routinely coadministered with primaquine (PQ) for radical cure of vivax malaria. Here we randomly assigned 204 uncomplicated vivax malaria patients from Juruá Valley, northwestern Brazil, to receive either sequential (arm 1) or concomitant (arm 2) CQ-PQ treatment. Because PQ may synergize the blood schizontocidal effect of CQ and mask low-level CQ resistance, we monitored CQ-only efficacy in arm 1 subjects, who had PQ administered only at the end of the 28-day follow-up. We found adequate clinical and parasitological responses in all subjects assigned to arm 2. However, 2.2% of arm 1 patients had microscopy-detected parasite recrudescences at day 28. When PCR-detected parasitemias at day 28 were considered, response rates decreased to 92.1% and 98.8% in arms 1 and 2, respectively. Therapeutic CQ levels were documented in 6 of 8 recurrences, consistent with true CQ resistance in vivo. In contrast, ex vivo assays provided no evidence of CQ resistance in 49 local P. vivax isolates analyzed. CQ-PQ coadministration was not found to potentiate the antirelapse efficacy of PQ over 180 days of surveillance; however, we suggest that larger studies are needed to examine whether and how CQ-PQ interactions, e.g., CQ-mediated inhibition of PQ metabolism, modulate radical cure efficacy in different P. vivax-infected populations. (This study has been registered at ClinicalTrials.gov under identifier NCT02691910.)

Published
2019

2. The mosaic of autoimmunity the role of environmental factors

Author

Rosa Maria Rodrigues Pereira, Shoenfeld Y, and de Carvalho Jf

Subjects
Epstein-Barr Virus Infections, General Immunology and Microbiology, business.industry, Multiple sclerosis, Smoking, Vaccination, Congenital cytomegalovirus infection, Autoimmunity, Environmental Exposure, Environmental exposure, medicine.disease, medicine.disease_cause, General Biochemistry, Genetics and Molecular Biology, Virus, Autoimmune Diseases, Immune system, Stress, Physiological, Rheumatoid arthritis, Cytomegalovirus Infections, Immunology, medicine, Humans, business, Epstein–Barr virus infection
Abstract

The "mosaic of autoimmunity" describes the multifactorial origin and diversity of expression of autoimmune diseases in humans. The term implies that different combinations of the many factors that are involved in auto-immunity produce varying and unique clinical pictures in a wide spectrum of autoimmune diseases. Most of the factors involved in autoimmunity can be categorized into four groups: genetic, immune defects, hormonal and environmental factors. In this communication, only the environmental factors are reviewed such as: infectious agents (represented by Epstein-Barr virus and cytomegalovirus), vaccines as triggers of autoimmunity, smoking and its relationship with rheumatoid arthritis, systemic lupus erythematosus, thyroid disease, multiple sclerosis and inflammatory bowel diseases. Some aspects of stress as implicated in causing autoimmunity and the processes leading to autoimmunity are reviewed as well.

Published
2009

3. P210Long- term outcome of primary mitral valve prolapse: results from a population of 250 patients referred to a tertiary cardiovascular center.P211Rheumatic Heart Disease in Uganda - Results from more than 600 echocardiograms in a no-profit hospitalP212Higher ventricular ectopy burden in asymptomatic severe Barlows mitral valve disease compared to similar patients with mitral valve prolapseP213Surgical mitral valve repair for severe secondary mitral regurgitation: prognostic implications of left ventricular forward flowP214Multicentre trial results of a transfemoral annuloplasty system for mitral valve reconstruction -P215Comparative assessment of paravalvular leaks with 3D-transesophageal echocardiography and cardiac computed tomographyP216Failing surgical aortic bioprosthetic valves: redo aortic valve surgery versus percutaneous valve-in-valve replacementP217Mitral annular calcification and infective endocarditisP218Infective endocarditis - a changing diseaseP219Staphilococcus aureus bacteremia: application of the ESC proposed diagnostic echocardiographic algorithm in clinical practiceP220ESC proposed diagnostic echocardiographic algorithm in elective patients with clinical suspicion of infective endocarditis and negative blood cultures: diagnostic yield and prognostic implicationsP221Three-dimensional transesophageal echocardiography versus multidetector computed tomography for aortic annulus sizing in TAVI: a worthy alternativeP222Early and mid-term improvement in left ventricular function after transcatheter aortic valve replacement as assessed by myocardial strain imagingP223Dynamic of aortic root as predictor of paravalvular regurgitation after transcatheter aortic valve implantationP224Short term effect of heart rate reduction by Ivabradine on left ventricular function and remodeling in systolic heart failure patientsP225Global longitudinal strain and regional longitudinal strain in patients with hypertrophic cardiomyopathy: are they associated with the presence of myocardial fibrosis?P226Investigation of mitral leaflet elongation in patients with non-obstructive versus latent-obstructive hypertrophic cardiomyopathyP227Hypertrophic cardiomyopathy: to what degree have the new ESC guidelines been implemented in routine clinical practice? A retrospective audit assessing current practice in a large general UK hospitalP228New genotype-phenotype associations in hypertrophic cardiomyopathy patients studied with cardiac magnetic resonance with feature-trackingP229How many are too many - frequent premature ventricular contractions and left ventricular functionP230Two-dimensional global longitudinal strain and strain rate for evaluation of inflammatory cardiomyopathy as proven by endomyocardial biopsyP231The echocardiographic features of young asymptomatic screening population with left ventricular hypertrabeculationP232Use of amlodipine to decrease myocardial iron in thalassemia major (AMIT trial): comparison of T2* CMR and echocardiography for assessment of cardiac volumes and functionP233Echocardiographic comparison of Fabry cardiomyopathy and light-chain amyloid heart diseaseP234Early detection of left atrial enlargement using 3D echocardiography in patients undergoing breast cancer treatment

Author

Mecarocci, V., primary, Mapelli, M., primary, Johnson, K., primary, Kamperidis, V., primary, Treede, H., primary, Alonso Fernandez De Gatta, M., primary, Mameri, A., primary, Pressman, G., primary, Coutinho Cruz, M., primary, Bartolacelli, Y., primary, Gillebert, C., primary, Lozano-Granero, VC., primary, Boretti, I., primary, Son, JW., primary, Carvalho, JF., primary, Zuo, L., primary, Basu, J., primary, Gomes, AC., primary, Lie, OH., primary, Aleksandrov, AS., primary, Tang, HC., primary, Alvi, N., primary, Marek, J., primary, Rascon Sabido, R., primary, Mori, F., additional, Fusini, L., additional, Zagni, P., additional, Muratori, M., additional, Agostoni, P., additional, Gripari, P., additional, Ghulam Ali, S., additional, Tamborini, G., additional, Pepi, M., additional, Fiorentini, C., additional, Abdel-Rahman, ST., additional, Dobson, L., additional, Kidambi, A., additional, Gatenby, K., additional, Schlosshan, D., additional, Van Wijngaarden, SE., additional, Van Rosendael, PJ., additional, Kong Kok Fai, W., additional, Leung, M., additional, Sianos, G., additional, Ajmone Marsan, N., additional, Bax, JJ., additional, Delgado, V., additional, Nickenig, G., additional, Kuck, KH., additional, Baldus, S., additional, Vahanian, A., additional, Colombo, A., additional, Alfieri, O., additional, Topilsky, Y., additional, Grayburn, P., additional, Maisano, F., additional, Barreiro Perez, M., additional, Arribas Jimenez, A., additional, Martin Garcia, A., additional, Diaz Pelaez, E., additional, Rodriguez Collado, J., additional, Cruz Gonzalez, I., additional, Sanchez Fernandez, PL., additional, Urena Alcazar, M., additional, Cimadevilla, C., additional, Himbert, D., additional, Raffoul, R., additional, Verdonk, C., additional, Nataf, P., additional, Messika-Zeitoun, D., additional, Gartman, CH., additional, Obasare, E., additional, Melendres, E., additional, Malik, M., additional, Slipczuk, L., additional, Figueredo, V., additional, Ilhao Moreira, R., additional, Moura Branco, L., additional, Galrinho, A., additional, Coutinho Miranda, L., additional, Timoteo, AT., additional, Abreu, J., additional, Pinto Teixeira, P., additional, Fragata, J., additional, Cruz Ferreira, R., additional, Barbieri, A., additional, Bursi, F., additional, Mantovani, F., additional, Lugli, R., additional, Fabbri, M., additional, Mussini, C., additional, Boriani, G., additional, Perry, R., additional, Hecker, T., additional, Szpytma, M., additional, Joseph, M., additional, Fernandez-Santos, S., additional, Plaza-Martin, M., additional, Lopez-Fernandez, T., additional, De La Hera, JM., additional, Martinez-Monzonis, A., additional, La Canna, G., additional, Mesa, D., additional, Swaans, M., additional, Murzilli, R., additional, Echevarria, T., additional, Habib, G., additional, Zamorano, JL., additional, Fernandez-Golfin Loban, C., additional, Salido, L., additional, Gonzalez Gomez, A., additional, Garcia Martin, A., additional, Hinojar Baides, R., additional, Pardo, A., additional, Moya Mur, JL., additional, Ruiz Leria, S., additional, Hernandez Antolin, R., additional, Jimenez Nacher, JJ., additional, Zamorano Gomez, JL., additional, Kim, HJ., additional, Kim, BJ., additional, Choi, KW., additional, Lee, CH., additional, Kim, W., additional, Park, JS., additional, Shin, DG., additional, Kim, YJ., additional, Choi, JH., additional, Congo, K., additional, Neves, D., additional, Pais, J., additional, Guerreiro, R., additional, Picarra, B., additional, Santos, AR., additional, Bento, A., additional, Aguiar, J., additional, Wang, J., additional, Ta, SJ., additional, Kang, N., additional, Zhou, MY., additional, Guo, RQ., additional, Liu, L., additional, Thorsen, L., additional, Thomas, K., additional, Shabbir, A., additional, Balkhausen, K., additional, Bull, S., additional, Lopes, LR., additional, Cruz, I., additional, Almeida, AR., additional, Pereira, H., additional, Saberniak, J., additional, Dejgaard, LA., additional, Anfinsen, OG., additional, Hegbom, F., additional, Edvardsen, T., additional, Haugaa, KH., additional, Kasner, M., additional, Tschoepe, C., additional, Ho, JS., additional, Goh, LK., additional, Ding, ZP., additional, Tipoo, FA., additional, Chowdhury, D., additional, Colan, S., additional, Imran, A., additional, Raza, U., additional, Ashiqali, S., additional, Hasan, BS., additional, Mohty, D., additional, Palecek, T., additional, Golan, L., additional, Jaccard, A., additional, Lenhart, A., additional, Garcia Mendez Rosalba, RGM, additional, Martinez Hernandez Carlos, MHC, additional, Ibarra Quevedo David, DIQ, additional, and Almeida Gutierrez Eduardo, EAG, additional

Published
2016
Full Text
View/download PDF

4. Poster session 1GENERAL PRINCIPLESP194Ultrasound indexes of adipose tissue and lipid goals attainment in high and very high cardiovascular risk patientsTHE IMAGING EXAMINATIONP195Right ventricular global longitudinal strain provides higher prognostic value than right free wall longitudinal strain in patients with left heart diseaseP196Normal values of echocardiographlc left and right cardiac chambers dimensions as multifactorially determined by sex, level of physical activity, age, BMI, systolic blood pressure and heart rateAnatomy and physiology of the heart and great vesselsP197Echocardiographic phenotypes according to levels of oxygen consumption at peak exercise: findings from the EURO(pean) EX(ercise) population-based studyAnatomy and physiology of the heart and great vesselsP198Systemic vascular resistance and central arterial stiffness in relation to left ventricular geometry and diastolic function in essential hypertensionAssessment of diameters, volumes and massP199Left atrial diameter predicts a new diagnosis of paroxysmal atrial fibrillation in a population presenting with palpitationsP200Interventricular septum thickness and acute coronary syndromes: small differences, big prognostic influence?P201Detection of abdominal aortic aneurysm in a population referred for an ultrasonographyAssessments of haemodynamicsP202The ultrasound vector velocity method transverse oscillation validated in a flowrig with constant and pulsatile flow and in-vivo of blood flow in the ascending aortaASSESSMENT OF SYSTOLIC FUNCTIONP203Different types of left ventrical remodeling in children with arterial hypertensionP204Assessment of myocardial performance index in hypertensive patients with or without hyperuricemiaP205Strain echocardiography detects mild impairment of systolic function in patients with frequent premature ventricular contractionsP206Speckle tracking strain correlates better with functional capacity and hemodynamic burden than ejection fraction in patients with severe heart failureP207Prognostic value of 2D and 3D echocardiographic volumes, ejection fraction and strain as markers of abnormal left ventricular performanceP208Long-term prognostic value of left ventricular ejection fraction assessed by echocardiography and magnetic resonance imaging after acute STEMIP209Assessment of left ventricular function after percutaneous coronary intervention of chronic total occluded coronary artery by speckle tracking and cardiac magnetic resonanceP210Physiologic variations of tricuspid annular plane systolic excursion in healthy subjects: clinical and echocardiographic correlatesP211Predictors of incipient ventricular dysfunction with tyrosine kinase inhibitors in metastatic renal cell carcinomaAssessment of diastolic functionP212Disagreement between the American Society of Echocardiography (ASE) and gastroenterology-based guidelines for the diagnosis of diastolic dysfunction among patients with advanced liver diseaseP213Nomograms for mitral inflow doppler and tissue doppler velocities in caucasian childrenP215Diastolic function is impaired in women with angina pectoris and no obstructive coronary artery disease independently of coronary microvascular functionP216Clinical value of myocardial performance index in patients with isolated diastolic dysfunctionIschemic heart diseaseP217Cardiac imaging strategy is clinically more effective and at lower cost than traditional ETT strategy for the diagnosis of stable coronary artery diseaseP218Does the ESC clinical pretest probability score stratify our patients correctly? Validation with stress echocardiographyP219Incremental value of exercise echocardiography over exercise electrocardiography in a chest pain unit: a decision curve analysisP220A bedside echocardiographic score for risk stratification of ST-elevation myocardial infarction patients undergoing primary percutaneous coronary interventionP221Interventricular and intraventricular dyssynchrony in patients with Q-wave acute myocardial infarctionP222Comparison of tagging and tissue tracking for myocardial strain assessment at 1.5T and 3.0T following ST-segment elevation myocardial infarctionP223Left atrial strain rate evaluated by two-dimensional speckle tracking is predictor of left ventricular arrhythmias in STEMI patients treated by primary PCIP224Impact of percutaneous coronary intervention of chronic total oclussion on left ventricular function using speckle tracking and cardiac magnetic resonanceHeart valve DiseasesP225Clinical and echocardiographic characteristics of patients with low flow severe aortic stenosis and preserved ejection fractionP226Ventricular-arterial interplay in patients with severe aortic stenosis: additional role of wave intensity analysisP227Degenerative aortic stenosis: don't forget the vascular componentP228Reclassifying low gradient aortic stenosis with 3D transesophageal echocardiography and global longitudinal strainP229Importance of mitral regurgitation on pre- and postoperative clinical status and echocardiographic findings in patients with severe aortic stenosis admitted for aortic valve replacementsP230Aorto-septal angle and degenerative aortic stenosis: a case-control study stenosisP231Difference of sST2 level in mitral stenosis compare with control subjectsP232Velocity-time integral of aortic regurgitation: a novel echocardiographic marker in the evaluation of aortic regurgitation severityP233Color doppler 3D echocardiography-derived regurgitant volume in primary mitral regurgitation: a comparison of different techniques with magnetic resonanceP234Outcome of surgery for degenerative mitral regurgitationP235Mitral valve repair or replacement for functional regurgitation and left ventricular dysfunction: clinical and echocardiographic outcomeP236Prevalence, characteristics and prognosis of moderate to severe tricuspid regurgitation in patients with precapillary pulmonary hypertensionP237Management of late bioprosthetic mitral valve thrombosisP238Relationship between pulmonary venous flow and prosthetic mitral valve thrombosisP239Transcatheter aortic valve implantation does not reduce acutely valvuloarterial impedance in an elderly population with degenerative calcific aortic valve stenosisP240Influence of type of prosthesis on mitral regurgitation change after transcatheter aortic valve replacement for aortic stenosisP241The prevalence of valve disease in patients undergoing atrial fibrillation ablationCardiomyopathiesP242The prognostic value of lung ultrasound at discharge in heart failureP243Prognostic value of global longitudinal strain in non-ischaemic dilated cardiomyopathyP244Additional effect of high intensity exercise training to cardiac resynchronization in heart failure: the reduction on left venticular massP245Dobutamine-induced changes of longitundinal strain predicts longterm mortality in severe heart failureP246Myocardial fibrosis is not related to two-dimensional longitudinal strain in dilated cardiomyopathyP247Echocardiographic parameters are predictors of positive genetic study in a Portuguese population with hypertrophic cardiomyopathy: a multicentre studyP248Myocardial deformation techniques for the evaluation of the right ventricle in fabry diseaseP249Borderline hypertrophic cardiomyopathy or athlete's heart: what is the role for genetic testing in athletes?P250Isolated papillary muscle hypertrophy. Clinical, electrocardiographic and morphologic characteristicsP251Prognostic value of the assessment of left atrial deformation in hypertrophic cardiomyopathyP252Assessment of subtle echocardiographic changes may improve risk stratification of arrhythmias in early stages of arrhythmogenic right ventricular cardiomyopathy (ARVC)P253Long-term correlation of electrocardiography with structural echocardiography changes in patients with arrhythmogenic right ventricular cardiomyopathyP254Right ventricular strain and dyssynchrony assessment in arrhythmogenic right ventricular cardiomyopathy: a cardiac magnetic resonance feature-tracking studyP255Association of non compaction and hypertrophic cardiomyopathies, Noonan and long QT syndromesP256Predictors of mortality in patients with acute myocarditisP257Clinical characteristics and natural history of acute myocarditisP258One-beat 3dimensional echocardiography for the assessment of right ventricular function in heart transplant recipientsP259Hemodynamically irrelevant, non-surgery related pericardial effusion is a predictor of mortality in heart transplanted patientsSystemic diseases and other conditionsP260Left ventricular function as a cardiac marker of target organ damage in non-diabetic, never treated hypertensive patients: Camparison with microalbuminuriaP261Subclinical myocardial dysfunction in hypertensive patients with hyperuricemiaP262Can deformation indices (strain/strain rate) establish differential diagnosis in infiltrative cardiomyopathies?P263Prevalence and factors associated with inappropriately high left ventricular mass in patients with rheumatoid arthritisP264Echocardiographic evaluation of patients with end-stage liver disease, the importance of follow up after liver transplantationP265Cardiovasclular involvement in asymptomatic juvenile localized scleroderma patientsP267Can the left ventricular mechanics using speckle tracking echocardiography in pregnancy predict the new onset heart failure?P268What causes impaired exercise tolerance in HFpEF? Relative contribution from LV filling pressure and other factorsCongenital heart diseaseP269Pregnancy in patients with Ebsteins anomaly - echocardiographic and clinical studyP270Double aortic arch anomalies in clinical practiceP271Echocardiography as the essential imaging modality in congenital heart disease - first one to begin with and the one who staysMasses, tumors and sources of embolismP272Can the reduction of wall shear stress in diskinetic myocardial wall segments be used to predict trombogenicity?Diseases of the aortaP273The role of modified transoesophageal echocardiography for optimal access decision making for transcatheter aortic valve replacement proceduresStress echocardiographyP274Is aortic valve resistance different in patients with severe aortic stenosis and left ventricular fraction below 40% with low or high gradient?P275Does wall motion score index in dobutamine stress echocardiography predict syntax score in catheterization lab?P276Sex-related differences in peak stress left ventricular global longitudinal strain during dobutamine stress echocardiography in patients with significant coronary artery diseaseP277Exercise stress echocardiography complications: a 4-year single center experienceP278Reduced baseline left ventricular longitudinal systolic function is a marker of inducible myocardial ischemia in patients undergoing exercise echocardiographyP279Estimation of mean pulmonary arterial pressure based on right ventricle systolic pressure observed from exercise echocardiography among non-pulmonary hypertension with systemic sclerosisTransesophageal echocardiographyP280Transoesophageal echocardiography in patients with neuroendocrine tumour and carcinoid symptoms is safe without intravenous octreotideP281The feasibility and the clinical benefit of the cognitive-behavioral intervention for preparing patients for transesophageal echocardiographic studyP282Dynamic changes of mitral annulus shape in different types of mitral valve prolapse. A three-dimensional transoesophageal studyReal-time three-dimensional TEEP283Severe aortic stenosis: evaluation of effective and anatomy valve by 2D transthoracic echocardiography and 3D transesophageal echocardiographyP2843D-transeosphageal echocardiography usefulness for assessment of cardiac output in intensive care unit: an ultrasound versus thermodilution comparative study for patients under mechanical ventilationP285The predictive value of three-dimensional vena-contracta in determining the number of MitraClip devices needed during the procedure in functional mitral regurgitationTissue Doppler and speckle trackingP286Should the septum be included in the assessment of right ventricular longitudinal strain?P287Can machine learning help to identify heart failure with preserved ejection fraction?P288Concordance of atrial function measurement by 3D volumetric echocardiography and speckle tracking deformation imagingP289Heterogonous regional diastolic function revealed by 2D speckle tracking echocardiography identifies patients with ischemic etiology of left ventricular systolic dysfunctionP290The values from Real time 3-dimensional strain is not independent from preload changesP291Risk stratification in hypertrophic cardiomyopathy. a potential role for speckle-tracking parameters by cardiac magnetic resonanceP292Abnormal longitudinal peak systolic strain in asymptomatic patients with type-I diabetes mellitusP294Strain evaluation of subclinical cardiac dysfunction in patients with myotonic dystrophy type 1P295Heart function assessment in perinatal asphyxia; speckle tracking indices from greyscale recordings perform better than from tissue Doppler recordings, fractional shortening and tissue Doppler indicesP297Longitudinal strain assessed by automatic function imaging - a useful tool in significant coronary artery disease detection in patients with low risk anginaP298Global 2-Dimensional strain as a predictor of mortality in heart transplant patients with cardiac allograft vasculopathyP299Two-dimensional longitudinal strain and strain rate in asymptomatic middle-aged patients with type 2 diabetes mellitus - a pilot study resultsP300Limited accuracy of myocardial deformation imaging in diagnosis of left ventricular segmental dysfunction in patients with acute myocardial infarction: is it only a limitation of the strain software?Computed Tomography & Nuclear CardiologyP301Evaluation of the actual prevalence of myocardial ischemia in patients prior to performing a peripheral vascular surgeryP302Prognostic value of myocardial ischemia detected by myocardial perfusion imaging in asymptomatic patients with diabetes type 2P303Economic cost analysis derived by coronary computed tomography angiography inappropriate indications to rule out coronary heart disease

Author

Haberka, M, primary, Garcia Martin, A, primary, Barbier, P, primary, Pellegrino, M, primary, Angelis, A, primary, Howlett, PJ, primary, Madeira, M, primary, Carrero, PJ, primary, Hansen, KL, primary, Trunina, I, primary, Basar, C, primary, Lie, OH, primary, Sade, LE, primary, Gopal, A S, primary, Klug, G, primary, Rodriguez Gonzalez, E, primary, Ferrara, F, primary, Moustafa, S, primary, Naksuk, N, primary, Cantinotti, M, primary, Michelsen, MM, primary, Fernandes, JMG, primary, Demir, OM, primary, Cano Carrizal, R, primary, Bouzas-Mosquera, A, primary, Leao, S, primary, Kuznetsov, VA, primary, Nazir, S A, primary, Trifunovic, D, primary, Spampinato, RA, primary, Antonini-Canterin, F, primary, Ribeiro, JM, primary, Morgado, GJ, primary, Reis, L, primary, Naratrekoon, B, primary, Soto-Ruiz, RM, primary, Penicka, M, primary, Zilberszac, R, primary, De Chiara, B, primary, Rifai, R, primary, Gunduz, S, primary, Cersit, S, primary, Devecchi, C, primary, Ancona, F, primary, Smith, D, primary, Gargani, L, primary, Asmarats Serra, L, primary, Abreu, A, primary, Ikonomidis, I, primary, Biernacka, B, primary, Gomes, AC, primary, Caballero, L, primary, Mansencal, N, primary, Venturini, C, primary, Zaroui, A, primary, Leren, I S, primary, Astrom Aneq, M, primary, Nucifora, G, primary, Rocon, CRLA, primary, Cho, J Y, primary, Stampfli, S F, primary, Cho, EJ, primary, Stevanovic, A, primary, Pena, J L, primary, Ognibeni, F, primary, Colunga, S, primary, Borowiec, A, primary, Hristova, K, primary, Kosmala, W, primary, Lesniak-Sobelga, A M, primary, Kaldararova, M, primary, Stanojevic, D, primary, Carbonell San Roman, A, primary, Hoetink, A, primary, Ferreira, R, primary, Rohani, A, primary, Wierzbowska-Drabik, K, primary, Carvalho, J F, primary, Cherubini, A, primary, Teramoto, K, primary, May, CJH, primary, Wejner-Mik, P, primary, Gurzun, M M, primary, Perea, GO, primary, Laveau, F, primary, Mahmoud, HM, primary, Sanz, M, primary, Sanchez-Martinez, S, primary, Montserrat, S, primary, Kowalczyk, E, primary, Park, CS, primary, Hinojar, R, primary, Van Berendoncks, A M, primary, Guedes, H, primary, Nestaas, E, primary, Onut, R, primary, Moran, L, primary, Kisko, A, primary, Agmon, Y, primary, Corneli, M, primary, Peovska Mitevska, IPM, primary, Barreiro Perez, M, primary, Banska, K, additional, Gasior, Z, additional, Moya-Mur, JL, additional, Carbonell-San Roman, S-A, additional, Rodriguez-Munoz, D, additional, Garcia-Lledo, A, additional, Casas-Rojo, E, additional, Hinojar, R, additional, Jimenez-Nacher, JJ, additional, Fernandez-Golfin, C, additional, Zamorano-Gomez, JL, additional, Ravani, A, additional, Cefalu, C, additional, Maltagliati, A, additional, Frigerio, B, additional, Sansaro, D, additional, Amato, M, additional, Baldassarre, D, additional, Bandera, F, additional, Generati, G, additional, Labate, V, additional, Alfonzetti, E, additional, Guazzi, M, additional, Aggeli, K, additional, Ioakeimidis, N, additional, Abdelrasoul, M, additional, Felekos, I, additional, Gourgouli, I, additional, Aznaouridis, K, additional, Rousakis, G, additional, Vlachopoulos, C, additional, Tousoulis, D, additional, Darasz, K, additional, Mahmoudi, M, additional, Shah, N, additional, Jabr, RI, additional, Hickman, M, additional, Leatham, EW, additional, Fry, CH, additional, Teixeira, R, additional, Almeida, I, additional, Caetano, F, additional, Fernandes, A, additional, Cassandra, M, additional, Reis, L, additional, Costa, M, additional, Goncalves, L, additional, Nielsen, AJ, additional, Carrero, MC, additional, Saubidet, GL, additional, Peralta, SP, additional, Moeller-Soerensen, H, additional, Kjaergaard, J, additional, Jensen, MB, additional, Lund, JT, additional, Pedersen, MM, additional, Olesen, JB, additional, Jensen, JA, additional, Nielsen, MB, additional, Sharykin, AS, additional, Karelina, EV, additional, Telezhnikova, ND, additional, Ozhan, H, additional, Kayapinar, O, additional, Albayrak, ES, additional, Saberniak, J, additional, Dejgaard, L, additional, Nestaas, E, additional, Edvardsen, T, additional, Haugaa, KH, additional, Bal, U, additional, Eroglu, S, additional, Pirat, B, additional, Muderrisoglu, H, additional, Muthukumar, L, additional, Saha, SK, additional, Toole, RS, additional, Reinstadler, S, additional, Feistritzer, HJ, additional, Pernter, B, additional, Mayr, A, additional, Franz, WM, additional, Mueller, S, additional, Metzler, B, additional, Mingo Santos, S, additional, Palomero Monivas, V, additional, Gonzalez Mirelis, J, additional, Goirigolzarri Artaza, J, additional, Zorita Gil, B, additional, Fernandez Diaz, JA, additional, Goicolea Ruigomez, J, additional, Restrepo Cordoba, MA, additional, Alonso Pulpon, L, additional, Gargani, L, additional, D'alto, M, additional, Ghio, S, additional, Acri, E, additional, Carannante, L, additional, Argiento, P, additional, D'andrea, A, additional, Vriz, O, additional, Bossone, E, additional, Ho, TH, additional, Shah, P, additional, Murphy, K, additional, Nelluri, BK, additional, Lee, H, additional, Wilansky, S, additional, Mookadam, F, additional, Peeraphatdit, T, additional, Chaiteerakij, R, additional, Klarich, KW, additional, Scalese, M, additional, Melo, M, additional, Assanta, N, additional, Marotta, M, additional, Crocetti, M, additional, Spadoni, I, additional, Giordano, R, additional, Kutty, S, additional, Iervasi, I, additional, Mygind, ND, additional, Pena, A, additional, Frestad, D, additional, Hoest, N, additional, Prescott, E, additional, Romao, BO, additional, Rivera, IR, additional, Mendonca, MA, additional, Carvalho, AC, additional, Campos, O, additional, Amato, A, additional, Moises, VA, additional, Bashir, A, additional, Marshall, K, additional, Douglas, M, additional, Wasan, B, additional, Plein, S, additional, Alfakih, K, additional, Casanova Rodriguez, C, additional, Cadenas Chamorro, R, additional, Iglesias Del Valle, D, additional, Martin-Penato Molina, A, additional, De Juan Baguda, J, additional, Prieto Moriche, E, additional, Garcia Garcia, A, additional, De La Cruz Berlanga, E, additional, Plaza Perez, I, additional, Peteiro, J, additional, Broullon, FJ, additional, Alvarez-Garcia, N, additional, Barbeito-Caamano, C, additional, Larranaga-Moreira, JM, additional, Maneiro-Melon, N, additional, Martinez-Ruiz, D, additional, Yanez, JC, additional, Vazquez-Rodriguez, JM, additional, Cordeiro, F, additional, Magalhaes, P, additional, Moz, M, additional, Trigo, J, additional, Mateus, P, additional, Fontes, P, additional, Moreira, I, additional, Krinochkin, DV, additional, Plusnin, AV, additional, Soldatova, AM, additional, Shetye, A, additional, Khan, JN, additional, Singh, A, additional, Kanagala, P, additional, Swarbrick, DJ, additional, Graham-Brown, M, additional, Mccann, GP, additional, Krljanac, G, additional, Savic, L, additional, Asanin, M, additional, Aleksandric, S, additional, Lasica, R, additional, Srdic, M, additional, Zlatic, N, additional, Petrovic, M, additional, Mrdovic, I, additional, Monivas Palomero, V, additional, Rivero Arribas, B, additional, Dobrovie, M, additional, Da Rocha E Silva, JG, additional, Bonamigo Thome, F, additional, Kluttig, R, additional, Schloma, V, additional, Dmitrieva, Y, additional, Strotdrees, E, additional, Mohr, FW, additional, Luzza, G, additional, Caruso, R, additional, Belfiore, R, additional, Della Mattia, A, additional, Poli, S, additional, Zito, C, additional, La Carrubba, S, additional, Carerj, S, additional, Carvalho, JF, additional, Gomes, AC, additional, Caldeira, D, additional, Cruz, IR, additional, Stuart, B, additional, Maia, R, additional, Fazendas, P, additional, Pereira, H, additional, Rakocevic, I, additional, Tutos, V, additional, Petrovic, O, additional, Boricic-Kostic, M, additional, Stepanovic, J, additional, Jovanovic, I, additional, Banovic, M, additional, Vujisic-Tesic, B, additional, Leite, L, additional, Madeira, M, additional, Botelho, A, additional, Santos, M, additional, Nascimento, J, additional, Yingchoncharoen, T, additional, Vathesatogkit, P, additional, Yamwong, S, additional, Sritara, P, additional, Bonaque Gonzalez, J C, additional, Abellan-Huerta, J, additional, Rubio-Paton, R, additional, Soria, F, additional, Ramos, JL, additional, Egea, S, additional, Garcia-Gomez, J, additional, Martinez Diaz, JJ, additional, Castillo, JA, additional, Vecera, J, additional, Mirica, C, additional, Kotrc, M, additional, Kockova, R, additional, Gabriel, H, additional, Maurer, G, additional, Rosenhek, R, additional, Botta, L, additional, Musca, F, additional, Belli, O, additional, Costetti, A, additional, Trolese, I, additional, Spano, F, additional, Russo, C, additional, Giannattasio, C, additional, Moreo, A, additional, Berthelot, E, additional, Le, MT, additional, Hilpert, L, additional, Montani, D, additional, Sitbon, O, additional, Jais, X, additional, Humbert, M, additional, Assayag, P, additional, Yesin, M, additional, Kalcik, M, additional, Gursoy, MO, additional, Cersit, S, additional, Astarcioglu, MA, additional, Karakoyun, S, additional, Aykan, AC, additional, Ozkan, M, additional, Gunduz, S, additional, Tabakci, M, additional, Bayam, E, additional, Degiovanni, A, additional, Di Ruocco, MV, additional, Marino, P, additional, Rosa, I, additional, Stella, S, additional, Barletta, M, additional, Marini, C, additional, Latib, A, additional, Montorfano, M, additional, Colombo, A, additional, Margonato, A, additional, Agricola, E, additional, Ray, R, additional, Gallagher, M, additional, Nazir, M, additional, Perreso, V, additional, Sharma, R, additional, Pang, PS, additional, Miglioranza, M, additional, Landi, P, additional, Dini, FL, additional, Picano, E, additional, Pons Llinares, J, additional, Macaya Ten, F, additional, Pericas Ramis, P, additional, Caldes Llull, O, additional, Grau Sepulveda, A, additional, Frontera, G, additional, Bethencourt, A, additional, Santa Clara, H, additional, Santos, V, additional, Oliveira, M, additional, Cunha, P, additional, Portugal, G, additional, Rio, P, additional, Branco, L, additional, Ferreira, R, additional, Mota Carmo, M, additional, Paraskevaidis, I, additional, Papadopoulos, C, additional, Stasinos, V, additional, Parissis, J, additional, Lekakis, J, additional, Rubis, P, additional, Gackowski, A, additional, Wisniowska-Smialek, S, additional, Lesniak-Sobelga, A, additional, Kostkiewicz, M, additional, Bento, D, additional, Correia, E, additional, Teles, L, additional, Picarra, B, additional, Lourenco, C, additional, Faria, R, additional, Domingues, K, additional, Azevedo, O, additional, Climent Paya, V, additional, Martinez Moreno, M, additional, Gimeno, JR, additional, Oliva, MJ, additional, Saura, D, additional, Sanchez Quinones, J, additional, Garcia Honrubia, A, additional, Valdes, M, additional, De La Morena, G, additional, Richard, P, additional, Guerard, S, additional, Brion, R, additional, Paul, P, additional, Dubourg, O, additional, Komajda, M, additional, Isnard, R, additional, Arslan, M, additional, Charron, P, additional, Avegliano, G, additional, Andres, S, additional, Costabel, JP, additional, Kuschnir, P, additional, Sciancalepore, A, additional, Mendoza, O, additional, Perea, G, additional, Ronderos, R, additional, Ben Said, RYM, additional, EL Chalbia, TEJ, additional, Wali, SANA, additional, Mourali, MS, additional, Mechmeche, RACHID, additional, Haland, TF, additional, Svetlichnaya, J S, additional, Shikha, SS, additional, Scheinmann, MS, additional, Klein, LK, additional, Prati, G, additional, Vitrella, G, additional, Allocca, G, additional, Cukon Buttignoni, S, additional, Muser, D, additional, Morocutti, G, additional, Pinamonti, B, additional, Sinagra, G, additional, Proclemer, A, additional, Melo, MDTM, additional, Bocchi, EAB, additional, Araujo, JABAF, additional, Demarchi, LMMFD, additional, Mady, CM, additional, Biselli, BB, additional, Kalil, RKF, additional, Salemi, VMCS, additional, Tuma, RT, additional, Kim, K H, additional, Yoon, H J, additional, Lee, K J, additional, Park, H, additional, Kim, J H, additional, Ahn, Y, additional, Jeong, M H, additional, Cho, J G, additional, Park, J C, additional, Park, H J, additional, Kozan, H, additional, Sezgin, A, additional, Aydinalp, A, additional, Oezkartal, T, additional, Bernhart, S, additional, Flammer, AJ, additional, Vecchiati, A, additional, Froehlich, GM, additional, Ruschitzka, F, additional, Tanner, FC, additional, Choi, KY, additional, Kim, DB, additional, Jang, SW, additional, Cho, JS, additional, Park, CS, additional, Jung, HO, additional, Jeon, HK, additional, Youn, HJ, additional, Dekleva, M, additional, Fortes, PRL, additional, Passos, BR, additional, Rodrigues, AB, additional, Sampaio, IH, additional, Oliveira, MCN, additional, Silva, MG, additional, Cardoso, RAF, additional, Tofani, FA, additional, Moreira, MCV, additional, Cioffi, G, additional, Viapiana, O, additional, Dalbeni, A, additional, Fracassi, E, additional, Di Nora, C, additional, Cherubini, A, additional, Mazzone, C, additional, Di Lenarda, A, additional, Rossini, M, additional, Corros, C, additional, Garcia-Campos, A, additional, Martin, M, additional, Rodriguez-Suarez, M, additional, Leon, V, additional, Fidalgo, A, additional, Lopez-Iglesias, F, additional, Moris, C, additional, De La Hera, JM, additional, Dabrowski, R, additional, Wozniak, J, additional, Jasek, S, additional, Chwyczko, T, additional, Kowalik, I, additional, Musiej-Nowakowska, E, additional, Szwed, H, additional, Marinov, R, additional, Stamenov, G, additional, Mihova, M, additional, Chacheva, K, additional, Persenska, S, additional, Racheva, A, additional, Przewlocka-Kosmala, M, additional, Rojek, A, additional, Karolko, B, additional, Mysiak, A, additional, Marwick, TH, additional, Biernacka, B, additional, Tittel, P, additional, Kardos, M, additional, Vrsanska, V, additional, Ondriska, M, additional, Hraska, V, additional, Nosal, M, additional, Masura, J, additional, Simkova, I, additional, Apostolovic, S, additional, Salinger-Martinovic, S, additional, Jankovic-Tomasevic, R, additional, Djordjevic-Radojkovic, D, additional, Stanojlovic, T, additional, Atanaskovic, V, additional, Pavlovic, M, additional, Tahirovic, E, additional, Dungen, HD, additional, Moya Mur, JL, additional, Lozano Granero, C, additional, Jimenez Nacher, JJ, additional, Gonzalez Gomez, A, additional, Fraile Sanz, C, additional, Segura De La Cal, T, additional, Zamorano Gomez, JL, additional, Jansen Klomp, WW, additional, Van 'T Hof, AWJ, additional, Brandon Bravo Bruinsma, GJ, additional, Spanjersberg, AJ, additional, Grandjean, J, additional, Nierich, AP, additional, Ferreira, J, additional, Lazaro Mendes, S, additional, Martins, R, additional, Monteiro, S, additional, Pego, M, additional, Khamene Bagheri, R, additional, Peruga, JZ, additional, Sobczak, M, additional, Plewka, M, additional, Wcislo, T, additional, Krecki, R, additional, Kasprzak, JD, additional, Morgado, G, additional, Cruz, I, additional, Almeida, AR, additional, Joao, I, additional, Lopes, L, additional, Cotrim, C, additional, Faganello, G, additional, Pandullo, C, additional, Russo, G, additional, Stefenelli, C, additional, Furlanello, F, additional, Tarantini, L, additional, Suzuki, K, additional, Satoh, Y, additional, Minami, K, additional, Mizukoshi, K, additional, Kamijima, R, additional, Kou, S, additional, Takai, M, additional, Izumo, M, additional, Akashi, YJ, additional, Ayuk, J, additional, Geh, I, additional, Shah, T, additional, Edwards, NC, additional, Steeds, RP, additional, Miskowiec, D, additional, Wdowiak-Okrojek, K, additional, Lipiec, P, additional, Rosca, M, additional, Calin, A, additional, Beladan, C, additional, Serban, M, additional, Ginghina, C, additional, Popescu, BA, additional, Lombardero, M, additional, Henquin, R, additional, Corneli, M, additional, Tinetti, M, additional, Hekimian, G, additional, Achkar, M, additional, Combes, A, additional, Hammoudi, N, additional, Al-Ghamdi, M, additional, Ghabashi, A, additional, Ezzat, M H, additional, Al-Amin, A, additional, Giraldeau, G, additional, Sarvari, SI, additional, Marin, J, additional, Brambila, C, additional, Gabrielli, L, additional, Bijnens, B, additional, Sitges, M, additional, Duchateau, N, additional, Erdei, T, additional, Fraser, A, additional, Bijnens, B H, additional, Piella, G, additional, Sanchis, L, additional, Borras, R, additional, Vidal, B, additional, Prat, S, additional, Azqueta, M, additional, Pare, C, additional, Grazioli, G, additional, Sanz, M, additional, Wejner-Mik, P, additional, Jung, MH, additional, Ahn, HS, additional, Kim, JH, additional, Megias, A, additional, Alonso, GL, additional, Gonzalez-Gomez, A, additional, Rincon, LM, additional, Esteban, A, additional, Fernandez Mendez, MA, additional, Barrios, V, additional, Zamorano, JL, additional, Van Gaal, L, additional, De Block, C, additional, Salgado, R, additional, Vrints, C, additional, Shivalkar, B, additional, Pereira, A, additional, Santos, R, additional, Marques, L, additional, Moreno, N, additional, Carvalho, R, additional, Pires, M, additional, Sousa, R, additional, Andrade, A, additional, Pinto, P, additional, Stoylen, A, additional, Fugelseth, D, additional, Tautu, O, additional, Onciul, S, additional, Marinescu, C, additional, Zamfir, D, additional, Dorobantu, M, additional, Sanchez Sanchez, V, additional, Navas, P, additional, Garcia-Cosio, D, additional, Diaz, B, additional, Carballo-Alzola, L, additional, Lombera, F, additional, Delgado, J, additional, Babcak, M, additional, Kishko, N, additional, Eitan, A, additional, Mutlak, D, additional, Kehat, I, additional, Meretta, AH, additional, Perea, GO, additional, Belcastro, F, additional, Aguirre, E, additional, Rosa, D, additional, Zaefferer, P, additional, Masoli, O, additional, Srbinovska, ES, additional, Bosevski, MB, additional, Antova, EA, additional, Pop Gorceva, DPG, additional, Martin Fernandez, M, additional, Costilla Garcia, SM, additional, Diaz Pelaez, E, additional, and Moris De La Tassa, C, additional

Published
2015
Full Text
View/download PDF

5. Rheumatoid Arthritis Associated with Vitiligo

Author

de Carvalho Jf

Subjects
Male, medicine.medical_specialty, business.industry, Vitiligo, Autoimmunity, Middle Aged, medicine.disease, Dermatology, Arthritis, Rheumatoid, 030207 dermatology & venereal diseases, 03 medical and health sciences, 0302 clinical medicine, Rheumatology, 030220 oncology & carcinogenesis, Rheumatoid arthritis, medicine, Humans, business
Published
2016

6. Prognostic evaluation of early rheumatoid arthritis

Author

dos Santos-Neto Ll, de Carvalho Jf, Laurindo Im, and da Mota Lm

Subjects
musculoskeletal diseases, medicine.medical_specialty, Exacerbation, Disease, Severity of Illness Index, Arthritis, Rheumatoid, Disability Evaluation, Internal medicine, Surveys and Questionnaires, medicine, Humans, Subclinical infection, Ultrasonography, business.industry, General Medicine, Early rheumatoid arthritis, medicine.disease, Prognosis, Magnetic Resonance Imaging, Rheumatology, Rheumatoid arthritis, Antirheumatic Agents, Joint damage, Physical therapy, Disease Progression, Quality of Life, business, Rheumatism
Abstract

Summary The progression of rheumatoid arthritis (RA) is quite variable, ranging from very mild or subclinical forms (approx. 10%) to rapidly progressing and debilitating forms (10‐15%). The majority of patients present with an intermediate stage with episodes of exacerbation separated by periods of relative inactivity, which evolves to progressive functional losses. To optimise the therapeutic management of early RA it is necessary to perform periodic evaluations of the clinical and laboratory test responses to the treatment instituted, as well as the parameters indicating disease prognosis. Composite measures are frequently used to evaluate the disease activity score (DAS), including the response criteria of the American College of Rheumatology (ACR), the response criteria and the DAS according to the European League Against Rheumatism (EULAR) and the composite indices of disease activity (CIDsA): DAS, the index of disease activity based on 28 joints (DAS 28), the simplified disease activity index (SDAI) and the clinical disease activity index (CDAI). The evaluation of prognosis includes investigation of the absence or occurrence of disease and joint damage remission. Due to the multifaceted nature of RA, no single clinical or laboratory parameter is able to describe satisfactorily the level of inflammatory activity or the disease prognosis at any given time.

Published
2010

7. Comportamento de Biomphalaria glabrata variantes albina e melânica frente à infecção pelo Schistosoma mansoni

Author

Allegretti,SM., Carvalho,JF., Magalhães,LA., and Zanotti-Magalhães,EM.

Subjects
parasitic diseases, esporocistos, amoebocytes, Schistosoma mansoni, amebócitos, Biomphalaria glabrata, sporocysts
Abstract

The behaviour of the albino and melanic variants of Biomphalaria glabrata of Belo Horizonte (MG. Brazil) was studied comparatively, in terms of their respective susceptibilities to infection by Schistosoma mansoni of the same origin, through observation of the elimination of cercariae for a three-month period and the calculation of mortality and infection rates, in control and in infected snails. The number of amoebocytes, granulocytes and hyalinocytes in the circulating hemolymph during different periods of infection was analyzed. The evolution of the infection in the tissues was observed by means of histological cross-sections. The melanic variant showed greater susceptibility to infection and a higher mortality rate. The albino variant showed a higher number of circulating amoebocytes, both granulocytes and hyalinocytes. A higher number of degenerated sporocysts were seen in the histological cross-sections of the albino variant. The results suggest that the melanic variant of B. glabrata was more susceptible to infection by S. mansoni than was the albino variant. Foi estudado comparativamente o comportamento das variantes albina e melânica de Biomphalaria glabrata de Belo Horizonte (MG. Brasil), em relação à susceptibilidade à infecção pelo Schistosoma mansoni de mesma origem, através da observação da eliminação de cercárias por um período de três meses e a verificação das taxas de mortalidade e infecção nos moluscos controles e infectados. Analisou-se também, o número de amebócitos granulócitos e hialinócitos na hemolinfa circulante em diferentes períodos de infecção. A evolução da infecção nos tecidos foi observada através de cortes histológicos. A variante melânica apresentou maior susceptibilidade à infecção e maior taxa de mortalidade. A variante albina apresentou maior número de amebócitos circulantes, tanto granulócitos quanto hialinócitos. Nos cortes histológicos foi verificado maior número de esporocistos degenerados na variedade albina. Por estes resultados sugere-se que nas populações estudadas a variante melânica de B. glabrata, foi mais susceptível à infecção pelo S. mansoni.

Published
2009

8. The mosaic of autoimmunity: hormonal and environmental factors involved in autoimmune diseases--2008

Author

Shoenfeld, Y., Zandman Goddard, G., Stojanovich, L., Cutolo, M., Amital, H., Levy, Y., Abu Shakra, M., Barzilai, O., Berkun, Y., Blank, M., De Carvalho Jf, Andrea Doria, Gilburd, B., Katz, U., Krause, I., Langevitz, P., Orbach, H., Pordeus, V., Ram, M., Toubi, E., and Sherer, Y.

Subjects
Epstein-Barr Virus Infections, Vaccines, Pregnancy, Stress, Physiological, Smoking, Humans, Female, Hormones, Stress, Psychological, Autoimmune Diseases, Circadian Rhythm
Published
2008

9. The Synthesis and Evaluation of Macrocyclic Gadolinium-DTPA-bis (amide) Complexes as Magnetic Resonance Imaging Contrast Agents

Author

Chang Ca, Kim Sh, Alan D. Watson, Fellmann Jd, Carvalho Jf, Crofts Sp, and John Varadarajan

Subjects
Gadolinium DTPA, Molecular Structure, Chemistry, Lability, Dimer, Gadolinium, Contrast Media, chemistry.chemical_element, General Medicine, Pentetic Acid, Magnetic Resonance Imaging, Metal, Mice, chemistry.chemical_compound, Crystallography, Monomer, visual_art, Amide, Organometallic Compounds, cardiovascular system, visual_art.visual_art_medium, Animals, DOTA, Moiety, Radiology, Nuclear Medicine and imaging
Abstract

The authors found that DTPA bis(amide) macrocycles can be prepared in reasonable yields using simple methods and readily available starting materials. Gadolinium complexation is facile and gives rise to monomeric and dimeric species. The "pocket size" influences the solid state structure of the final complex, with Gd-DTPA-EAM existing as a dimer wherein the macrocycle bridges between two metal centers. Increasing the size of the bridging diamide moiety yields a macrocycle with a sufficiently large pocket to allow for the formation of nine-coordinant monomeric complexes. The solution behavior of all the complexes studied is consistent with the complex being present as monomers. All complexes display kinetic lability comparable to Gd-DTPA-BMA. The measured KTherm and KSel values of the complexes vary with the size of the pocket. Values similar to those observed for Gd-DTPA-BMA have been obtained with Gd-DTPA-OAM. There appears to be a good correlation between log K(Gd/Zn) and the acute toxicity for the complexes studied, with Gd-DTPA-OAM showing a toxicity value similar to that of Gd-DTPA-BMA. Although many of these complexes are chemically interesting, they do not offer any unique advantages as new magnetic resonance imaging contrast agents compared with the DOTA- and DTPA-based products currently used clinically.

Published
1994

29. Moderate/severe erectile dysfunction in patients with antiphospholipid syndrome.

Author

Lopes Gallinaro, A, Silva, CA, Rabelo Junior, CN, Correia Caleiro, MT, and de Carvalho, JF

Subjects
ANTIPHOSPHOLIPID syndrome, IMPOTENCE, HEALTH of patients, LUPUS erythematosus, RHEUMATISM
Abstract

Purpose: To evaluate sexual function of antiphospholipid syndrome (APS) patients using the Brazilian version of the validated International Index of Erectile Function (IIEF).Materials and methods: Eleven APS male patients (Sapporo criteria) were age and race-matched with 22 healthy controls. Demographic and clinical data, drug use and antiphospholipid antibodies were evaluated. The IIEF was also self-applied.Results: Mean age (p = 0.114), frequency of Caucasian race (p = 1.00) and married status (p = 0.438) were similar in APS and controls. Mean disease duration was 8.8 ± 4.6 years. Erectile dysfunction (ED) was frequently observed in APS versus controls (45.5 vs. 4.5%, p = 0.0096), especially moderate/severe ED (p = 0.0081). The total IIEF score (49.6 vs. 67.1, p = 0.019), erectile function (19.6 vs. 28.1, p = 0.005) and intercourse satisfaction (7.8 vs. 11.9, p = 0.009) were lower in patients than in controls. No differences were seen in orgasmic function (p = 0.114), sexual desire (p = 0.123) or overall satisfaction (p = 0.097) between the groups. The comparison between APS patients with ED (n = 5) and without ED (n = 6) revealed more arterial events in APS with ED (100 vs. 16.7%, p = 0.0152), and also longer disease duration (12 [7–16] vs. 5.5 [2–13] years, p = 0.031). A trend towards lower venous events (20 vs. 83.3%, p = 0.0801) and higher renal thrombotic microangiopathy (60% vs. 0, p = 0.0606) was observed in APS patients with ED. Demographics, clinical manifestations, smoking and antiphospholipid antibodies positivity were similar in both groups.Conclusion: To our knowledge, this was the first study that demonstrated moderate/severe ED in almost 50% of cases of a rare autoimmune disease. This alteration was linked to arterial events and longer disease duration. [ABSTRACT FROM AUTHOR]

Published
2012
Full Text
View/download PDF

32. Anti-lipoprotein lipase antibodies: a new player in the complex atherosclerotic process in systemic lupus erythematosus?

Author

de Carvalho JF, Borba EF, Viana VST, Bueno C, Leon EP, and Bonfá E

Abstract

OBJECTIVE: The novel description of antibodies to lipoprotein lipase (anti-LPL) associated with dyslipoproteinemia prompted us to analyze the association of anti-LPL with clinical and serologic features in patients with systemic lupus erythematosus (SLE) and its link to markers of inflammation that are known to be involved in atherogenesis. METHODS: Enzyme-linked immunosorbent assay was used to test for the presence of anti-LPL antibodies in 66 consecutive patients with SLE. Clinical and laboratory evaluation, including a fasting lipid profile, autoantibody screening, an assessment for markers of inflammation (C-reactive protein [CRP], erythrocyte sedimentation rate [ESR]), and the SLE Disease Activity Index (SLEDAI) were performed at the time of inclusion in the study. Exclusion criteria were any conditions that affect the lipid profile. SLE patients were categorized into 2 groups according to detection of these anti-LPL antibodies, as follows: anti-LPL+ and anti-LPL-. RESULTS: Anti-LPL antibody IgG was detected in 25 SLE patients (37.8%). Triglyceride levels were significantly higher in the anti-LPL+ group (112.4 +/- 50.2 versus 89.9 +/- 54.5 mg/dl in the anti-LPL- group; P = 0.033), but no significant differences between the 2 groups were detected for total, high-density lipoprotein, and low-density lipoprotein cholesterol levels. A higher frequency of elevated CRP levels and ESRs was observed in the anti-LPL+ group compared with the anti-LPL- group (44% and 17.1%, respectively [P = 0.023] and 52% and 19.5%, respectively [P = 0.013]). Moreover, SLE patients with anti-LPL antibodies also had significantly higher levels of CRP (11.1 +/- 16.4 versus 2.4 +/- 2.6 mug/ml; P = 0.036) and higher ESRs (33.4 +/- 29.8 versus 16.5 +/- 11.8 mm/hour; P = 0.020). Anti-LPL titers had a significant positive correlation with the CRP level (r = 0.56, P < 0.001), the ESR (r = 0.55, P < 0.001), the SLEDAI score (r = 0.45, P < 0.001), anti-double-stranded DNA (anti-dsDNA; r = 0.52, P < 0.001), and anticardiolipin IgG antibodies (r = 0.25, P = 0.04), and a significant negative correlation was detected with total hemolytic complement activity (CH100) (r = -0.34, P = 0.005). Reinforcing these findings, multiple regression analysis also revealed a significant association of anti-LPL with the CRP level (P = 0.025) and anti-dsDNA (P < 0.001). Importantly, a comparison of positive and negative anti-dsDNA sera revealed similar mean CRP levels (P = 0.56) and ESRs (P = 0.102), contrasting with the SLEDAI score (P = 0.004) and CH100 (P = 0.008). CONCLUSION: These data support the link between inflammation, immune response, and dyslipoproteinemia in SLE, introducing anti-LPL as a possible new player that may ultimately help in understanding the complex events of atherogenesis in this disease. [ABSTRACT FROM AUTHOR]

Published
2004
Full Text
View/download PDF

33. Estudo sobre a cópula interespecífica entre moluscos planorbídeos Biomphalaria glabrata e B. tenagophila

Author

de Carvalho Jf, Luis Alexandre Gonçalves Magalhães, and Kawazoe U

Subjects
biology, Public Health, Environmental and Occupational Health, Zoology, Biomphalaria glabrata, Interspecific competition, Mating, biology.organism_classification
Abstract

Foi estudada a freqüência da cópula interespecífica entre espécimes de Biomphalaria glabrata e B. tenagophila. Os resultados da experiência levaram a conclusão de que há preferência pela cópula intraespecífica, ocorrendo, contudo, cópulas interespecíficas.

Published
1973

34. Measles vaccine: induced specific antibody in normal and undernourished infants

Author

Raul Corrêa Ribeiro, Irene Skraba, Miguel Angel Lino Rodriguez, Maluf Em, and de Carvalho Jf

Subjects
Specific antibody, lcsh:Arctic medicine. Tropical medicine, Infectious Diseases, lcsh:RC955-962, business.industry, Immunology, Medicine, General Medicine, Measles vaccine, business
Abstract

Two hundred and twenty tree children were studied regarding their response to the measles vaccine. The antibody response was measured by hemaglutination inhibition technique. Among the variables studied only the children's age at the time the vaccine was done had influence on the seroconvertion. Sex and nutritional status had no influence on the seroconvertion. A theoric model was designed to find at what age the vaccine had the best effect in preventing mortality. The age predicte was seven months. Foi estudada a indução de anticorpos anti-sarampo em 223 crianças nutridas e desnutridas vacinadas entre 6 e 24 meses e naquelas que permaneceram soronegativas com 1 dose da vacina realizada antes dos 12 meses que foram revacinadas após os 12 meses. A determinação de anticorpos anti-sarampo foi realizada pelas técnicas de inibição da hemaglutinação e de soroneutralização. Observamos que a taxa de soroconversão aumentou progressivamente com a idade, sendo de 43% aos 6 meses e de 80% aos 15 meses. A taxa de soroconversão em crianças marasmáticas foi semelhante à obtida em crianças nutridas, concordando com a literatura que vem demonstrando que crianças desnutridas não apresentam alteração na capacidade de resposta humoral à vacina. Utilizando os dados de mortalidade por sarampo e as taxas de soroconversão à vacina, idealizou-se um modelo hipotético para a avaliação da aplicação da vacina em diferentes idades e suas conseqüências em têrmos de mortalidade, e observou-se que quando a vacina é realizada em idades precoces (6-7 meses) o número de óbito esperado é inferior ao esperado quando a vacina é realizada em idades posteriores (9-11 meses), indicando que a proposta atual do Ministério da Saúde de aplicar dose única aos 9 meses, teoricamente aumentaria o risco de mortalidade. Considerando o número de crianças protegidas com 1 dose de vacina aplicada antes dos 12 meses e o número de crianças protegidas com a revacinação a taxa de soroconversão foi de 84,3%.

Published
1985

35. Poster session 1

Author

Haberka, M, Banska, K, Gasior, Z, Garcia Martin, A, Moya-Mur, JL, Carbonell-San Roman, S-A, Rodriguez-Munoz, D, Garcia-Lledo, A, Casas-Rojo, E, Hinojar, R, Jimenez-Nacher, JJ, Fernandez-Golfin, C, Zamorano-Gomez, JL, Barbier, P, Ravani, A, Cefalu, C, Maltagliati, A, Frigerio, B, Sansaro, D, Amato, M, Baldassarre, D, Pellegrino, M, Bandera, F, Generati, G, Labate, V, Alfonzetti, E, Guazzi, M, Angelis, A, Aggeli, K, Ioakeimidis, N, Abdelrasoul, M, Felekos, I, Gourgouli, I, Aznaouridis, K, Rousakis, G, Vlachopoulos, C, Tousoulis, D, Howlett, PJ, Darasz, K, Mahmoudi, M, Shah, N, Jabr, RI, Hickman, M, Leatham, EW, Fry, CH, PREDICT-PAF, Madeira, M, Teixeira, R, Almeida, I, Caetano, F, Fernandes, A, Cassandra, M, Reis, L, Costa, M, Goncalves, L, Carrero, PJ, Nielsen, AJ, Carrero, MC, Saubidet, GL, Peralta, SP, Argentina, Aorta Abdominal, Hansen, KL, Moeller-Soerensen, H, Kjaergaard, J, Jensen, MB, Lund, JT, Pedersen, MM, Olesen, JB, Jensen, JA, Nielsen, MB, Trunina, I, Sharykin, AS, Karelina, EV, Telezhnikova, ND, Basar, C, Ozhan, H, Kayapinar, O, Albayrak, ES, Lie, OH, Saberniak, J, Dejgaard, L, Nestaas, E, Edvardsen, T, Haugaa, KH, Sade, LE, Bal, U, Eroglu, S, Pirat, B, Muderrisoglu, H, Gopal, A S, Muthukumar, L, Saha, SK, Toole, RS, Klug, G, Reinstadler, S, Feistritzer, HJ, Pernter, B, Mayr, A, Franz, WM, Mueller, S, Metzler, B, Rodriguez Gonzalez, E, Mingo Santos, S, Palomero Monivas, V, Gonzalez Mirelis, J, Goirigolzarri Artaza, J, Zorita Gil, B, Fernandez Diaz, JA, Goicolea Ruigomez, J, Restrepo Cordoba, MA, Alonso Pulpon, L, Ferrara, F, Gargani, L, D'alto, M, Ghio, S, Acri, E, Carannante, L, Argiento, P, D'andrea, A, Vriz, O, Bossone, E, Moustafa, S, Ho, TH, Shah, P, Murphy, K, Nelluri, BK, Lee, H, Wilansky, S, Mookadam, F, Naksuk, N, Peeraphatdit, T, Chaiteerakij, R, Klarich, KW, Cantinotti, M, Scalese, M, Melo, M, Assanta, N, Marotta, M, Crocetti, M, Spadoni, I, Giordano, R, Kutty, S, Iervasi, I, Michelsen, MM, Mygind, ND, Pena, A, Frestad, D, Hoest, N, Prescott, E, Fernandes, JMG, Romao, BO, Rivera, IR, Mendonca, MA, Carvalho, AC, Campos, O, Amato, A, Moises, VA, Demir, OM, Bashir, A, Marshall, K, Douglas, M, Wasan, B, Plein, S, Alfakih, K, Cano Carrizal, R, Casanova Rodriguez, C, Cadenas Chamorro, R, Iglesias Del Valle, D, Martin-Penato Molina, A, De Juan Baguda, J, Prieto Moriche, E, Garcia Garcia, A, De La Cruz Berlanga, E, Plaza Perez, I, Bouzas-Mosquera, A, Peteiro, J, Broullon, FJ, Alvarez-Garcia, N, Barbeito-Caamano, C, Larranaga-Moreira, JM, Maneiro-Melon, N, Martinez-Ruiz, D, Yanez, JC, Vazquez-Rodriguez, JM, Leao, S, Cordeiro, F, Magalhaes, P, Moz, M, Trigo, J, Mateus, P, Fontes, P, Moreira, I, Kuznetsov, VA, Krinochkin, DV, Plusnin, AV, Soldatova, AM, Nazir, S A, Shetye, A, Khan, JN, Singh, A, Kanagala, P, Swarbrick, DJ, Graham-Brown, M, Mccann, GP, Trifunovic, D, Krljanac, G, Savic, L, Asanin, M, Aleksandric, S, Lasica, R, Srdic, M, Zlatic, N, Petrovic, M, Mrdovic, I, Rodriguez Gonzalez, E, Mingo Santos, S, Monivas Palomero, V, Gonzalez Mirelis, J, Zorita Gil, B, Fernandez Diaz, JA, Restrepo Cordoba, MA, Goirigolzarri Artaza, J, Rivero Arribas, B, Goicolea Ruigomez, J, Spampinato, RA, Dobrovie, M, Da Rocha E Silva, JG, Bonamigo Thome, F, Kluttig, R, Schloma, V, Dmitrieva, Y, Strotdrees, E, Mohr, FW, Antonini-Canterin, F, Luzza, G, Caruso, R, Belfiore, R, Della Mattia, A, Poli, S, Vriz, O, Zito, C, La Carrubba, S, Carerj, S, Ribeiro, JM, Teixeira, R, Goncalves, L, Morgado, GJ, Carvalho, JF, Gomes, AC, Caldeira, D, Cruz, IR, Stuart, B, Maia, R, Fazendas, P, Pereira, H, Trifunovic, D, Rakocevic, I, Tutos, V, Petrovic, O, Petrovic, M, Boricic-Kostic, M, Stepanovic, J, Jovanovic, I, Banovic, M, Vujisic-Tesic, B, Reis, L, Teixeira, R, Leite, L, Fernandes, A, Cassandra, M, Madeira, M, Botelho, A, Santos, M, Nascimento, J, Goncalves, L, Naratrekoon, B, Yingchoncharoen, T, Vathesatogkit, P, Yamwong, S, Sritara, P, Soto-Ruiz, RM, Bonaque Gonzalez, J C, Abellan-Huerta, J, Rubio-Paton, R, Soria, F, Ramos, JL, Egea, S, Garcia-Gomez, J, Martinez Diaz, JJ, Castillo, JA, Penicka, M, Vecera, J, Mirica, C, Kotrc, M, Kockova, R, Zilberszac, R, Gabriel, H, Maurer, G, Rosenhek, R, De Chiara, B, Botta, L, Musca, F, Belli, O, Costetti, A, Trolese, I, Spano, F, Russo, C, Giannattasio, C, Moreo, A, Rifai, R, Berthelot, E, Le, MT, Hilpert, L, Montani, D, Sitbon, O, Jais, X, Humbert, M, Assayag, P, Gunduz, S, Yesin, M, Kalcik, M, Gursoy, MO, Cersit, S, Astarcioglu, MA, Karakoyun, S, Aykan, AC, Ozkan, M, Cersit, S, Gunduz, S, Tabakci, M, Kalcik, M, Yesin, M, Bayam, E, Ozkan, M, Devecchi, C, Degiovanni, A, Di Ruocco, MV, Marino, P, Ancona, F, Rosa, I, Stella, S, Barletta, M, Marini, C, Latib, A, Montorfano, M, Colombo, A, Margonato, A, Agricola, E, Smith, D, Ray, R, Gallagher, M, Nazir, M, Perreso, V, Sharma, R, Gargani, L, Pang, PS, Miglioranza, M, Landi, P, Dini, FL, Picano, E, Asmarats Serra, L, Pons Llinares, J, Macaya Ten, F, Pericas Ramis, P, Caldes Llull, O, Grau Sepulveda, A, Frontera, G, Bethencourt, A, Abreu, A, Santa Clara, H, Santos, V, Oliveira, M, Cunha, P, Portugal, G, Rio, P, Branco, L, Ferreira, R, Mota Carmo, M, Ikonomidis, I, Paraskevaidis, I, Papadopoulos, C, Stasinos, V, Parissis, J, Lekakis, J, Biernacka, B, Rubis, P, Gackowski, A, Wisniowska-Smialek, S, Lesniak-Sobelga, A, Kostkiewicz, M, Gomes, AC, Bento, D, Correia, E, Teles, L, Picarra, B, Lourenco, C, Faria, R, Magalhaes, P, Domingues, K, Azevedo, O, Caballero, L, Climent Paya, V, Martinez Moreno, M, Gimeno, JR, Oliva, MJ, Saura, D, Sanchez Quinones, J, Garcia Honrubia, A, Valdes, M, De La Morena, G, Mansencal, N, Richard, P, Guerard, S, Brion, R, Paul, P, Dubourg, O, Komajda, M, Isnard, R, Arslan, M, Charron, P, Venturini, C, Avegliano, G, Andres, S, Costabel, JP, Kuschnir, P, Sciancalepore, A, Mendoza, O, Perea, G, Ronderos, R, Zaroui, A, Ben Said, RYM, EL Chalbia, TEJ, Wali, SANA, Mourali, MS, Mechmeche, RACHID, Leren, I S, Saberniak, J, Haland, TF, Edvardsen, T, Haugaa, KH, Astrom Aneq, M, Svetlichnaya, J S, Shikha, SS, Scheinmann, MS, Klein, LK, Nucifora, G, Prati, G, Vitrella, G, Allocca, G, Cukon Buttignoni, S, Muser, D, Morocutti, G, Pinamonti, B, Sinagra, G, Proclemer, A, Rocon, CRLA, Melo, MDTM, Bocchi, EAB, Araujo, JABAF, Demarchi, LMMFD, Mady, CM, Biselli, BB, Kalil, RKF, Salemi, VMCS, Tuma, RT, Cho, J Y, Kim, K H, Yoon, H J, Lee, K J, Park, H, Kim, J H, Ahn, Y, Jeong, M H, Cho, J G, Park, J C, Cho, J Y, Kim, K H, Yoon, H J, Park, H J, Kim, J H, Ahn, Y, Jeong, M H, Cho, J G, Park, J C, Sade, LE, Kozan, H, Eroglu, S, Pirat, B, Sezgin, A, Aydinalp, A, Muderrisoglu, H, Stampfli, S F, Oezkartal, T, Bernhart, S, Flammer, AJ, Vecchiati, A, Froehlich, GM, Ruschitzka, F, Tanner, FC, Cho, EJ, Choi, KY, Kim, DB, Jang, SW, Cho, JS, Park, CS, Jung, HO, Jeon, HK, Youn, HJ, Stevanovic, A, Dekleva, M, Pena, J L, Fortes, PRL, Passos, BR, Rodrigues, AB, Sampaio, IH, Oliveira, MCN, Silva, MG, Cardoso, RAF, Tofani, FA, Moreira, MCV, Ognibeni, F, Cioffi, G, Viapiana, O, Dalbeni, A, Fracassi, E, Di Nora, C, Cherubini, A, Mazzone, C, Di Lenarda, A, Rossini, M, Colunga, S, Corros, C, Garcia-Campos, A, Martin, M, Rodriguez-Suarez, M, Leon, V, Fidalgo, A, Lopez-Iglesias, F, Moris, C, De La Hera, JM, Borowiec, A, Dabrowski, R, Wozniak, J, Jasek, S, Chwyczko, T, Kowalik, I, Musiej-Nowakowska, E, Szwed, H, Hristova, K, Marinov, R, Stamenov, G, Mihova, M, Chacheva, K, Persenska, S, Racheva, A, Kosmala, W, Przewlocka-Kosmala, M, Rojek, A, Karolko, B, Mysiak, A, Marwick, TH, Lesniak-Sobelga, A M, Kostkiewicz, M, Wisniowska-Smialek, S, Biernacka, B, Rubis, P, Kaldararova, M, Tittel, P, Kardos, M, Vrsanska, V, Ondriska, M, Hraska, V, Nosal, M, Masura, J, Simkova, I, Stanojevic, D, Apostolovic, S, Salinger-Martinovic, S, Jankovic-Tomasevic, R, Djordjevic-Radojkovic, D, Stanojlovic, T, Atanaskovic, V, Pavlovic, M, Tahirovic, E, Dungen, HD, Carbonell San Roman, A, Moya Mur, JL, Rodriguez-Munoz, D, Lozano Granero, C, Jimenez Nacher, JJ, Gonzalez Gomez, A, Fraile Sanz, C, Segura De La Cal, T, Fernandez-Golfin, C, Zamorano Gomez, JL, Hoetink, A, Jansen Klomp, WW, Van 'T Hof, AWJ, Brandon Bravo Bruinsma, GJ, Spanjersberg, AJ, Grandjean, J, Nierich, AP, Ferreira, R, Ferreira, J, Lazaro Mendes, S, Martins, R, Monteiro, S, Pego, M, Rohani, A, Khamene Bagheri, R, Wierzbowska-Drabik, K, Peruga, JZ, Sobczak, M, Plewka, M, Wcislo, T, Krecki, R, Kasprzak, JD, Carvalho, J F, Morgado, G, Cruz, I, Caldeira, D, Almeida, AR, Joao, I, Lopes, L, Fazendas, P, Cotrim, C, Pereira, H, Cherubini, A, Cioffi, G, Mazzone, C, Faganello, G, Pandullo, C, Russo, G, Stefenelli, C, Furlanello, F, Tarantini, L, Di Lenarda, A, Teramoto, K, Suzuki, K, Satoh, Y, Minami, K, Mizukoshi, K, Kamijima, R, Kou, S, Takai, M, Izumo, M, Akashi, YJ, May, CJH, Ayuk, J, Geh, I, Shah, T, Edwards, NC, Steeds, RP, Wejner-Mik, P, Sobczak, M, Miskowiec, D, Wdowiak-Okrojek, K, Kasprzak, JD, Lipiec, P, Gurzun, M M, Rosca, M, Calin, A, Beladan, C, Serban, M, Ginghina, C, Popescu, BA, Perea, GO, Lombardero, M, Henquin, R, Corneli, M, Tinetti, M, Laveau, F, Hekimian, G, Achkar, M, Isnard, R, Combes, A, Hammoudi, N, Mahmoud, HM, Al-Ghamdi, M, Ghabashi, A, Ezzat, M H, Al-Amin, A, Sanz, M, Giraldeau, G, Sarvari, SI, Marin, J, Brambila, C, Gabrielli, L, Bijnens, B, Sitges, M, Sanchez-Martinez, S, Duchateau, N, Erdei, T, Fraser, A, Bijnens, B H, Piella, G, Montserrat, S, Sanchis, L, Borras, R, Vidal, B, Prat, S, Azqueta, M, Pare, C, Grazioli, G, Sanz, M, Sitges, M, Kowalczyk, E, Kasprzak, JD, Wejner-Mik, P, Wdowiak-Okrojek, K, Lipiec, P, Park, CS, Jung, MH, Ahn, HS, Kim, JH, Cho, JS, Jeon, HK, Youn, HJ, Hinojar, R, Fernandez-Golfin, C, Megias, A, Alonso, GL, Gonzalez-Gomez, A, Rincon, LM, Esteban, A, Fernandez Mendez, MA, Barrios, V, Zamorano, JL, Van Berendoncks, A M, Van Gaal, L, De Block, C, Salgado, R, Vrints, C, Shivalkar, B, Guedes, H, Pereira, A, Santos, R, Marques, L, Moreno, N, Carvalho, R, Pires, M, Sousa, R, Andrade, A, Pinto, P, Nestaas, E, Stoylen, A, Fugelseth, D, Onut, R, Tautu, O, Onciul, S, Marinescu, C, Zamfir, D, Dorobantu, M, Moran, L, Sanchez Sanchez, V, Navas, P, Garcia-Cosio, D, Diaz, B, Carballo-Alzola, L, Lombera, F, Delgado, J, Kisko, A, Babcak, M, Kishko, N, Agmon, Y, Eitan, A, Mutlak, D, Kehat, I, Corneli, M, Meretta, AH, Perea, GO, Belcastro, F, Aguirre, E, Rosa, D, Zaefferer, P, Masoli, O, Peovska Mitevska, IPM, Srbinovska, ES, Bosevski, MB, Antova, EA, Pop Gorceva, DPG, Barreiro Perez, M, Martin Fernandez, M, Costilla Garcia, SM, Diaz Pelaez, E, and Moris De La Tassa, C

Abstract

Background: The attainment of the primary (low density lipoprotein cholesterol; LDL-C) and the secondary (non-high density lipoprotein cholesterol; non-HDL) lipid therapeutic targets may depend on several potential factors. Our aim was assess the associations between ultrasound fat indexes, lipid levels and the lipid goals attainment in high and very high cardiovascular (CV) risk patients. Methods: Four hundred twenty (n=420) patients (F/M=146/274; age=61 ± 7 y.o.) with high (43%) or very high (57%) cardiovascular risk and chronic statin treatment (³12 months) were enrolled into the study. Obesity measures (body-mass index, BMI; bioelectrical impedance body fat; BF, waist circumference, WC, body adiposity index; BAI), serum levels of lipids (total cholesterol–TC, LDL-C, HDL-C and triglycerides–TG) and goal lipid levels (LDL-C and non-HDL-C) according to the CV risk were determined in all patients. The following ultrasound fat parameters were used in the study: intraabdominal fat (IAT), preperitoneal fat thickness (PreFT), epicardial (EFT) and pericardial (PFT) fat thickness and were indexed to BMI. Results: Our study patients had 5.2 ± 1.7 CV risk factors (80% hypertension, 32% diabetes, 59% metabolic syndrome), 49% were obese, 63% had high BF% and 85% had increased waist circumference (F>80 or M>94cm). All the patients were on a long-term statin treatment (rosuvastatin, atorvastatin or simvastatin). The attainment of the target lipid levels in the study group was as follows: LDL-C–34%, non-HDL-C–39%, both LDL-C and non-HDL-C 31%. Mean fat parameters in the study group were as follows: IAT–76.4 ± 26mm, PreFT–23.3 ± 6.5mm, EFT–3.5 ± 1.5mm and PFT–8.6 ± 3.8mm. Patients with LDL-C goal attainment had significantly higher BAI (34.6 ± 33 vs 30.5 ± 7, p=0.04), but significantly lower IAT/BMI (2.35 ± 0.7 vs 2.51 ± 0.7, p<0.05) with no differences in other clinical (BMI, BF%, WC) and ultrasound (PreFT/BMI, EFT/BMI, PFT/BMI) indexes. The LDL-C goal achievement revealed inverse association with IAT/BMI (r=-0.15, p<0.05) and no associations with PreFT/BMI, EFT/BMI or PFT/BMI. Multivariable regression analysis revealed independent association between IAT/BMI and the LDL-C goal achievement. Conclusions: Intraabdominal fat thickness representing visceral adipose tissue is inversely associated with the LDL-C goal attainment independently from general obesity. It may help to identify individuals requiring more aggressive management of dylipidaemia.

Published
2015
Full Text
View/download PDF

36. A novel 60 kDa reactivity in cyclic neutropenia: high titer cytoplasmic ANCA immunostaining pattern and negative anti-proteinase-3 antibody.

Author

Rodrigues CE, Velloso ER, Pereira RM, Bonfá E, Teixeira FK, Bueno C, Dorlhiac-Laccer PE, Kondo AT, Viana VS, Carvalho JF, Rodrigues, Camila E, Velloso, Elvira R P, Pereira, Rosa M R, Bonfá, Eloísa, Teixeira, Flávia K, Bueno, Cleonice, Dorlhiac-Laccer, Pedro E, Kondo, Andréa T, Viana, Vilma S T, and Carvalho, Jozélio F

Published
2011
Full Text
View/download PDF

37. Anti-lipoprotein lipase antibodies: A review.

Author

de Carvalho JF and Skare TL

Abstract

Background: Dyslipidemia is described in several autoimmune conditions. Lipoprotein lipase (LPL) is responsible for triglyceride breakdown. Anti-LPL antibodies have been described., Objective: To review articles on anti-LPL antibodies in autoimmune and non-autoimmune diseases., Results: Twenty-two articles were found: 9 case reports and 13 observational studies. In 5 of 9 case reports, hypertriglyceridemia normalized after immunosuppressive treatment. The observational studies showed the prevalence and associations of anti-LPL antibodies: systemic lupus erythematosus, found in 37.8 % to 71 % of patients and associated with nephritis, disease activity, and the presence of anti-dsDNA antibodies. In myositis, the prevalence ranged from 4 % to 43 % without any reported association. In scleroderma, they were found in 35 % to 42 % and associated with skin and lung fibrosis, heart involvement, and the presence of anti-topoisomerase-1 antibodies. In Sjögren's syndrome and rheumatoid arthritis, they were found in a minority of individuals. They were absent in Behçet's disease, antiphospholipid antibody syndrome, juvenile idiopathic arthritis, juvenile dermatomyositis, and Takayasu arteritis. Three studies were conducted on dyslipidemic patients without autoimmune conditions, and in one of them, anti-LPL antibodies were associated with necrosis in atherosclerotic plaques., Conclusion: Anti-LPL antibodies were detected in several autoimmune and non-autoimmune diseases, mainly connective tissue diseases, and were associated with increased triglyceride levels. These antibodies may contribute to the accelerated atherogenesis seen in these patients., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024. Published by Elsevier B.V.)

Published
2024
Full Text
View/download PDF

38. Ear abnormalities in chronic fatigue syndrome (CFS), fibromyalgia (FM), Coronavirus-19 infectious disease (COVID) and long-COVID syndrome (PCS), sick-building syndrome (SBS), post-orthostatic tachycardia syndrome (PoTS), and autoimmune/inflammatory syndrome induced by adjuvants (ASIA): A systematic review.

Author

Skare TL, de Carvalho JF, de Medeiros IRT, and Shoenfeld Y

Subjects
Humans, Autoimmune Diseases etiology, COVID-19 Vaccines adverse effects, Post-Acute COVID-19 Syndrome complications, SARS-CoV-2, COVID-19 complications, COVID-19 prevention & control, Fatigue Syndrome, Chronic complications, Fibromyalgia complications, Postural Orthostatic Tachycardia Syndrome complications
Abstract

Chronic fatigue syndrome (CFS), fibromyalgia (FM), silicone breast implants (SBI), Coronavirus-19 infectious disease (COVID), COVID-19 vaccination (post-COVIDvac-syndrome), Long-COVID syndrome (PCS), sick-building syndrome (SBS), post-orthostatic tachycardia syndrome (PoTS), and autoimmune/ inflammatory syndrome induced by adjuvants (ASIA) are a cluster of poorly understood medical conditions that have in common a group of ill-defined symptoms and dysautonomic features. Most of the clinical findings of this group of diseases are unspecific, such as fatigue, diffuse pain, cognitive impairment, paresthesia, tachycardia, anxiety, and depression. Hearing disturbances and vertigo have also been described in this context, the underlying pathophysiologic process for these conditions might rely on autonomic autoimmune dysbalance. The authors procced a literature review regarding to hearing and labyrinthic disturbances in CSF, FM, SBI, COVID, post-COVIDvac-syndrome, PCS, SBS, POTS, and ASIA. The PRISMA guidelines were followed, and the literature reviewed encompassed papers from January 1990 to January 2024. After the initial evaluation of the articles found in the search through Pubmed, Scielo and Embase, a total of 172 articles were read and included in this review. The prevalence of hearing loss, dizziness, vertigo and tinnitus was described and correlated with the diseases investigated in this study. There are great variability in the frequencies of symptoms found, but cochlear complaints are the most frequent in most studies. Vestibular symptoms are less reported. The main pathophysiological mechanisms are discussed. Direct effects of the virus in the inner ear or nervous pathways, impaired vascular perfusion, cross-reaction or autoimmune immunoreactivity, oxidative stress, DNA methylation, epigenetic modifications and gene activation were implicated in the generation of the investigated symptoms. In clinical practice, all patients with these autoimmune conditions who have any audiological complaint an ENT consultation followed by an audiometry are needed., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024. Published by Elsevier B.V.)

Published
2024
Full Text
View/download PDF

39. Ear Complaints in Fibromyalgia: A Narrative Review.

Author

Skare TL and de Carvalho JF

Abstract

Introduction: Patients with fibromyalgia (FM) have innumerable complaints due to the central amplification of somatic stimuli. The aim of this paper was to review the ear complaints in patients with FM., Methods: A review of articles published in PubMed/MEDLINE, Embase, Web of Science, and Scopus from 1966 to June 2023 was performed., Results: Seventeen papers were included in the review. They showed that patients with FM have a higher hearing loss rate, mostly at high frequencies, and hyperacusis. The prevalence of vestibular symptoms (tinnitus, dizziness) and hyperacusis was higher than in the general population, reaching 87.0% of the sample. Subjective findings did not always correspond to objective results. In some studies, the degree of FM severity was associated with ear symptoms; in others, it was not., Conclusions: Ear complaints in patients with FM are linked to subjacent disease and may be related to stimuli central amplification., (© 2024. The Author(s).)

Published
2024
Full Text
View/download PDF

40. Remote sensing in maize: effect of vegetal biostimulants application in three stages of development.

Author

Silva AV, Silva CM, Silva JHB, Pereira WE, Albuquerque MB, Medeiros JC, Leal FRR, Carvalho JF, Silva BOT, and Mielezrski F

Subjects
Plant Growth Regulators pharmacology, Zea mays growth & development, Remote Sensing Technology, Seasons
Abstract

Maize is a crop of global economic importance and is widely cultivated throughout the Brazilian territory. The use of biostimulants can increase yield and improve crop yield. Unmanned aerial vehicles can be employed in arable areas, allowing their use in an economically way. This study to evaluate the use of biostimulant and the best application timing using photogrammetric indexes in maize, and indicate the most suitable plant index for yield increase through a Pearson's correlation. The DJI Drone coupled with RGB camera was used, and the images were processed through the AgisoftPhotoscan® software to generate the orthomosaic, and the QGIS® software version 3.4.15 with GRASS was used to generate thematic maps with the classification of the indexes of vegetation (NGRDI, EXG, SAVI, TGI, GLI, RI). A matrix of Pearson correlation coefficients between the variables was also created, and the results were analyzed with the R software. In general, the products Pyroligneous Extract (PE) and the hormonal product (HP) were the best for the two seasons studied. However, the HP was the best product to mitigate plant water stress in the dry period. Application at phenological stage V3 showed the lowest growth in the rainy season and in application to the seeds in the dry season. Dose 4 of the pyroligneous extract increased productivity in the rainy season and level 3.4 for the hormone product. Among the indexes evaluated, only the SAVI index showed significant differences between the others and showed significance for productivity in the two periods.

Published
2024
Full Text
View/download PDF

41. High-dose Cyclophosphamide Without Stem Cell Rescue in Autoimmune Diseases: A Systematic Review.

Author

de Carvalho JF and Skare TL

Abstract

High-dose cyclophosphamide without stem cell rescue is a radical therapy for refractory autoimmune diseases. The objective was to review the results of high-dose cyclophosphamide without stem cell rescue in autoimmune diseases. PubMed, Scielo, and Embase databases were systematically searched for articles on high-dose cyclophosphamide without stem cell rescue treating autoimmune diseases between 1966 and September 2022. Twenty-nine studies were identified, including a total of 404 patients. The diseases most studied were systemic lupus erythematosus (n=113), multiple sclerosis (n=99), aplastic anemia (n=86), and myasthenia gravis (n=33). Most authors used the posology of 50mg/kg/day over four days of cyclophosphamide associated with Mesna, prophylactic antibiotics, G-CSF (granulocyte colony-stimulating factor), and support of red blood cells, and platelet transfusion. The most common side effects were febrile neutropenia, alopecia, and gastrointestinal complaints. Regarding outcomes, most of the studies demonstrated improvement of the underlying autoimmune disease, some long-lived, but relapses and failures were also identified. In conclusion, high-dose cyclophosphamide without stem cell rescue is an effective option for treating severe autoimmune diseases. This procedure is relatively safe when the appropriate supportive care measures are taken.

Published
2024
Full Text
View/download PDF

43. Successful Treatment of a Fibromyalgia Patient Using a Homeopathic Preparation of Cannabis sativa.

Author

Carvalho JF and Ribeiro MFLDS

Subjects
Humans, Female, Middle Aged, Phytotherapy methods, Treatment Outcome, Fibromyalgia drug therapy, Fibromyalgia therapy, Cannabis, Homeopathy methods
Abstract

Background: Homeopathy has been used in observational and controlled studies to treat patients with fibromyalgia (FM), but none has previously used the remedy Cannabis sativa ., Case History: A 51-year-old female patient presenting with diffuse pain and sleep disorder was diagnosed with FM using the relevant American College of Rheumatology criteria. She reported having 18 tender points, a pain score (visual analog scale, VAS) of 9.0, and a well-being VAS of 5.0. She was prescribed Cannabis sativa 6 cH, five drops sublingually thrice a day., Results: After 2 months, she returned asymptomatic, with 0 tender points, pain VAS of 0, and well-being VAS of 9.0. The Modified Naranjo Criteria for Homeopathy score was equal to +9, suggesting the clinical outcome was causally attributable to the medicine prescribed., Conclusion: This case study reveals the positive role of homeopathic treatment in FM. Studies using a randomized controlled design, including pragmatic trials to determine treatment effectiveness in real-world clinical practice, are indicated in this field., Competing Interests: None declared., (Faculty of Homeopathy. This article is published by Thieme.)

Published
2024
Full Text
View/download PDF

44. Ketamine in fibromyalgia: a systematic review.

Author

de Carvalho JF and de Sena EP

Subjects
Humans, Analgesics therapeutic use, Analgesics adverse effects, Analgesics administration & dosage, Female, Male, Adult, Middle Aged, Antidepressive Agents therapeutic use, Antidepressive Agents adverse effects, Pain Measurement, Infusions, Intravenous, Treatment Outcome, Ketamine therapeutic use, Ketamine administration & dosage, Ketamine adverse effects, Fibromyalgia drug therapy
Abstract

Objective: Fibromyalgia (FM) subjects are treated with antidepressant agents; in most cases, these drugs lose efficacy or have adverse effects. Ketamine is an anesthetic drug used in FM in some studies. This article aims to systematically review the safety and efficacy of ketamine in fibromyalgia (FM) patients., Materials and Methods: We systematically searched articles on FM and ketamine published at Pubmed from 1966 to 2021. This study was registered at PROSPERO., Results: There were only 6 articles published in this field, with a total of 115 patients. The female sex was predominant (88 to 100%). The age varied from 23 to 53 years old. Disease duration ranged from 1 month to 28 years. The dosage of ketamine changed from 0.1 mg/kg-0.3-0.5 mg/kg in intravenous infusion (4/5) and subcutaneous application (1/5). Regarding outcomes, the Visual analog scale (VAS) before ketamine was from 59 to 100 mm and after treatment from 2 to 95 mm. Most short-term studies had a good response. Only the study with 8 weeks of follow-up did not observe a good response. Side effects were common; all appeared during the infusion and disappeared after a few minutes of the ketamine injection., Conclusions: The present study demonstrates the effectiveness and safety of ketamine in FM patients in the short term. Although, more studies, including long-term follow-up studies, are still needed., (© 2024. The Author(s).)

Published
2024
Full Text
View/download PDF

45. Cannabis therapy in rheumatological diseases: A systematic review.

Author

de Carvalho JF, Ribeiro MFLDS, and Skare T

Abstract

Cannabis has been used in rheumatic diseases as therapy for chronic pain or inflammatory conditions. Herein, the authors systematically review the rheumatological diseases in which cannabis has been studied: systemic sclerosis, fibromyalgia, osteoarthritis, rheumatoid arthritis, osteoporosis, polymyalgia rheumatica, gout, dermatomyositis, and psoriatic arthritis. We systematically searched PubMed for articles on cannabis and rheumatic diseases between 1966 and March 2023. Twenty-eight articles have been selected for review. Most of them (n=13) were on fibromyalgia and all of them but one showed important reduction in pain; sleep and mood also improved. On rheumatoid arthritis, two papers displayed decrease in pain and in one of them a reduction in inflammatory parameters was found. In scleroderma there was a case description with good results, one study on local use for digital ulcers also with good outcomes and a third one, that disclosed good results for skin fibrosis. In dermatomyositis a single study showed improvement of skin manifestations and in osteoarthritis (3 studies) this drug has demonstrated a good analgesic effect. Several surveys (n=5) on the general use of cannabis showed that rheumatological patients (mixed diseases) do use this drug even without medical supervision. The reported side effects were mild. In conclusion, cannabis treatment is an interesting option for the treatment of rheumatological diseases that should be further explored with more studies., Competing Interests: No conflict of interest was declared by the authors.

Published
2024
Full Text
View/download PDF

46. Sexuality and sexual dysfunction in patients with psoriatic arthritis: A cross-sectional study.

Author

Lobo JN, Ramos LMA, Mont'Alverne ARS, de Carvalho JF, and Rodrigues CEM

Abstract

Objective: Psoriatic arthritis (PsA) is a chronic inflammatory disorder affecting the joints, skin and entheses. Despite the importance of the topic, few studies have investigated the association between PsA and sexual function. The purpose of this study was to assess sexuality and the prevalence of sexual dysfunction (SD) in patients with PsA., Methods: This was an observational, cross-sectional single-center study on 23 PsA patients (male=12; female=11) evaluated with 2 male questionnaires (MSQ= Male Sexual Quotient, and IIEF=International Index of Erectile Function) and 2 female questionnaires (FSQ= Female Sexual Quotient, and FSFI=Female Sexual Function Index) validated for Brazilian Portuguese, in order to determine changes in sexual function. Clinical parameters, musculoskeletal activity and skin activity were also analyzed to identify factors associated with SD., Results: The mean age was 52.1±9.7 years (males) and 49.1±9.6 years (females). Clinically, the patients had low skin and peripheral joint disease activity or were in remission. The mean time of PsA was 10±6.2 years, and 65.2% had a steady sexual partner. The mean MSQ score was 75.8±16.8. The prevalence of SD was 91.7% in men (IIEF), with a predominance of mild SD. The mean FSQ score was 64.9±24.1. The prevalence of SD was 72.7% in women (FSFI), with low domain scores. Also, a significant association was found between female age and total and domain-specific FSFI scores. PASI (Psoriasis Area and Severity Index) and the general satisfaction domain (IIEF) were significantly correlated., Conclusion: This study found a high prevalence of SD in PsA patients. Age had a negative impact on female sexual function. Physicians need to be more aware of SD in this population to provide early multidisciplinary treatment and minimize the impact of the disease on the quality of life of patients and their partners., Competing Interests: No conflict of interest was declared by the authors.

Published
2024
Full Text
View/download PDF

48. Health and lifestyle parameters in peripheral artery disease at two periods of the COVID-19 pandemic: comparison between men and women.

Author

Kanegusuku H, Silva GOD, Braghieri HA, Carvalho JF, Costa RM, Cucato GG, Wolosker N, Ritti-Dias RM, and Correia MA

Subjects
Male, Humans, Female, Pandemics, Longitudinal Studies, Life Style, COVID-19 epidemiology, Peripheral Arterial Disease epidemiology
Abstract

Objective: This study analyzed the impact of sex on self-reported health and lifestyle parameters in peripheral artery disease patients at two periods of the COVID-19 pandemic., Methods: In this longitudinal study, 99 patients with peripheral artery disease (53 men and 46 women) were evaluated during two periods of the COVID-19 pandemic ( i.e ., at onset: May to August 2020, and on follow-up: May to August 2021). Patients were interviewed via telephone, and information regarding lifestyle and health parameters was obtained., Results: At the onset of the COVID-19 pandemic, health and habit parameters were similar between women and men, with 63.0% and 45.3% indicating frequent fatigue, 73.9% and 84.9% reporting increased sitting time, and 23.9% and 39.6% practicing physical activity, respectively. At follow-up, difficulties in physical mobility (women: from 26.1% to 73.9%, p<0.001; men: from 39.6% to 71.7%, p=0.001) and the frequency of hospitalization for reasons other than COVID-19 increased similarly in women and men (women: from 4.3% to 21.7%, p=0.013; men: from 9.4% to 24.5%, p=0.038). The other parameters were similar between the periods., Conclusion: Self-reported physical mobility difficulties and hospitalization frequency increased in women and men with peripheral artery disease., Background: ▪ Sitting time increased in 73.9% of women and 84.9% of men at the onset of the pandemic., Background: ▪ Physical activity was practiced by 23.9% of women and 39.6% of men at the onset of the pandemic., Background: ▪ The prevalence of both women and men reporting physical mobility difficulties increased at follow-up., Background: ▪ Hospitalization rates for reasons unrelated to COVID-19 have increased in both women and., Background: While women experience more consequences related to peripheral artery disease than men, such as worse functional capacity and higher morbidity, there was a similar increase in physical mobility difficulty and frequency of hospitalization for reasons other than COVID-19 one year after the onset of the pandemic.

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results